Abstract
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Current Cancer Drug Targets
Title:Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Volume: 16 Issue: 5
Author(s): José Ángel García-Sáenz, Miguel Martín, Pilar Zamora, Ignasi Tusquets, Miguel Ángel Seguí, Ana Santaballa, Pedro Sánchez-Rovira, Manuel Ruiz, Álvaro Rodríguez-Lescure, Arrate Plazaola, Eduardo Martínez de Dueñas, Noelia Martínez-Jáñez, Guillermo López-Vivanco, Rafael López, Juan de la Haba, Antonio González-Martín, Andrés García-Palomo, Elena Galve, Lourdes Calvo, Norberto Batista, Agustí Barnadas, Francisco Ayala de la Peña, José Manuel Aramendía, Isabel Álvarez, Raquel Andrés, Ana Lluch, Antonio Llombart, Javier Cortés, Eva Ciruelos and Emilio Alba
Affiliation:
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Abstract: Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Export Options
About this article
Cite this article as:
Ángel García-Sáenz José, Martín Miguel, Zamora Pilar, Tusquets Ignasi, Ángel Seguí Miguel, Santaballa Ana, Sánchez-Rovira Pedro, Ruiz Manuel, Rodríguez-Lescure Álvaro, Plazaola Arrate, Martínez de Dueñas Eduardo, Martínez-Jáñez Noelia, López-Vivanco Guillermo, López Rafael, de la Haba Juan, González-Martín Antonio, García-Palomo Andrés, Galve Elena, Calvo Lourdes, Batista Norberto, Barnadas Agustí, Ayala de la Peña Francisco, Manuel Aramendía José, Álvarez Isabel, Andrés Raquel, Lluch Ana, Llombart Antonio, Cortés Javier, Ciruelos Eva and Alba Emilio, Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009615666150817121731
DOI https://dx.doi.org/10.2174/1568009615666150817121731 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Di- and Sesquiterpenoids from Cystoseira Genus: Structure, Intra-molecular Transformations and Biological Activity
Mini-Reviews in Medicinal Chemistry Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Benzofuran-Based Estrogen Receptor α Modulators as Anti-Cancer Therapeutics: In Silico and Experimental Studies
Current Medicinal Chemistry Chalcones and Chromones in Copper-Catalyzed Azide–Alkyne Cycloadditions (CuAAC)
Current Organic Chemistry Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design Development and Tailoring of Hybrid Lipid Nanocarriers
Current Pharmaceutical Design Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Current Drug Targets Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design A Pilot Study for Investigation of Plasma Amino Acid Profile in Neurofibromatosis Type 1 Patients
Combinatorial Chemistry & High Throughput Screening Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Drug Metabolism Letters NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design Nicotinamide Overcomes Doxorubicin Resistance of Breast Cancer Cells through Deregulating SIRT1/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry